The American journal on addictions
-
Despite greater rates of cannabis use among those that smoke combustible cigarettes, it is currently unknown whether cannabis use is related to e-cigarette dependence or maladaptive beliefs about combustible cigarettes. Therefore, the current study sought to identify whether adult dual users of combustible and e-cigarettes (ie, dual users) who also used cannabis differed from dual users who did not use cannabis on e-cigarette dependence severity, perceived barriers to quitting, and perception of risks and of benefits of e-cigarettes. ⋯ The present data extend current understanding of dual users by contextualizing cannabis use within e-cigarette and combustible cigarette use behaviors and highlight a potential substance use behavior that may be targetable in the framework of nicotine cessation. (Am J Addict 2020;00:00-00).
-
We implemented a naloxone education and distribution program in our academic health system. Despite the program, naloxone prescribing was not fully realized. This study aimed to identify the barriers to prescribing. ⋯ Our study addressed an unexplored area of OEND research and may inform future program development. (Am J Addict 2019;00:00-00).
-
Forty-nine out of 50 states have implemented Prescription Drug Monitoring Programs (PDMPs) to monitor controlled substance (CS) prescribing. PDMPs change health care provider behavior, but few studies have examined changes in CS prescription by health care provider type. ⋯ Changes in prescribing following introduction of mandatory use of KASPER markedly differed based on provider type, with increases observed for APRNs compared with physicians and dentists. These findings advance prior research by providing a detailed examination of prescribing trends by provider type subsequent to a PDMPs mandatory use law. (Am J Addict 2019;00:00-00).
-
Cannabis use is common in people with and mood and anxiety disorders (ADs), and rates of problematic use are higher than in the general population. Given recent policy changes in favor of cannabis legalization, it is important to understand how cannabis and cannabinoids may impact people with these disorders. We aimed to assess the effects of cannabis on the onset and course of depression, bipolar disorder, ADs, and post-traumatic stress disorder (PTSD), and also to explore the therapeutic potential of cannabis and cannabinoids for these disorders. ⋯ These conclusions are limited by a lack of well-controlled longitudinal studies. We suggest that future research be directed toward high-quality, prospective studies of cannabis in clinical populations with mood and ADs, in addition to controlled studies of cannabinoid constituents and pharmaceuticals in these populations. (Am J Addict 2019;00:00-00).
-
Despite the benefits of maintenance buprenorphine treatment for opioid use disorder (OUD), many individuals report an interest in discontinuing the medication, while also expressing worries about tapering. The purpose of this study was to develop a measure of worries about buprenorphine discontinuation ("Off Bupe") and determine the demographic and clinical characteristics associated with these worries. ⋯ The scale might help individuals with OUD and their providers identify concerns about discontinuing buprenorphine. (Am J Addict 2019;28:270-276).